Xencor | XNCR - Sales Revenues


Xencor reported $28.24M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025